TY - JOUR
T1 - Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis
AU - Teunissen, Charlotte
AU - Menge, Til
AU - Altintas, Ayse
AU - Álvarez-Cermeño, José C.
AU - Bertolotto, Antonio
AU - Berven, Frode S.
AU - Brundin, Lou
AU - Comabella, Manuel
AU - Degn, Matilde
AU - Deisenhammer, Florian
AU - Fazekas, Franz
AU - Franciotta, Diego
AU - Frederiksen, Jette L.
AU - Galimberti, Daniela
AU - Gnanapavan, Sharmilee
AU - Hegen, Harald
AU - Hemmer, Bernhard
AU - Hintzen, Rogier
AU - Hughes, Steve
AU - Iacobaeus, Ellen
AU - Kroksveen, Ann C.
AU - Kuhle, Jens
AU - Richert, John
AU - Tumani, Hayrettin
AU - Villar, Luisa M.
AU - Drulovic, Jelena
AU - Dujmovic, Irena
AU - Khalil, Michael
AU - Bartos, Ales
PY - 2013/11
Y1 - 2013/11
N2 - The choice of appropriate control group(s) is critical in cerebrospinal fluid (CSF) biomarker research in multiple sclerosis (MS). There is a lack of definitions and nomenclature of different control groups and a rationalized application of different control groups. We here propose consensus definitions and nomenclature for the following groups: healthy controls (HCs), spinal anesthesia subjects (SASs), inflammatory neurological disease controls (INDCs), peripheral inflammatory neurological disease controls (PINDCs), non-inflammatory neurological controls (NINDCs), symptomatic controls (SCs). Furthermore, we discuss the application of these control groups in specific study designs, such as for diagnostic biomarker studies, prognostic biomarker studies and therapeutic response studies. Application of these uniform definitions will lead to better comparability of biomarker studies and optimal use of available resources. This will lead to improved quality of CSF biomarker research in MS and related disorders.
AB - The choice of appropriate control group(s) is critical in cerebrospinal fluid (CSF) biomarker research in multiple sclerosis (MS). There is a lack of definitions and nomenclature of different control groups and a rationalized application of different control groups. We here propose consensus definitions and nomenclature for the following groups: healthy controls (HCs), spinal anesthesia subjects (SASs), inflammatory neurological disease controls (INDCs), peripheral inflammatory neurological disease controls (PINDCs), non-inflammatory neurological controls (NINDCs), symptomatic controls (SCs). Furthermore, we discuss the application of these control groups in specific study designs, such as for diagnostic biomarker studies, prognostic biomarker studies and therapeutic response studies. Application of these uniform definitions will lead to better comparability of biomarker studies and optimal use of available resources. This will lead to improved quality of CSF biomarker research in MS and related disorders.
KW - Biomarkers
KW - cerebrospinal fluid
KW - control groups
KW - study design
UR - http://www.scopus.com/inward/record.url?scp=84887524454&partnerID=8YFLogxK
U2 - 10.1177/1352458513488232
DO - 10.1177/1352458513488232
M3 - Review article
C2 - 23695446
AN - SCOPUS:84887524454
SN - 1352-4585
VL - 19
SP - 1802
EP - 1809
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 13
ER -